Shandong Weigao Blood

603014 · SHG · Healthcare / Medical Devices

35.00CNY+0.55 (+1.60%)

Price History

Full chart

Market Stats

Previous Close34.45

Open34.18

Day Range34.04 – 35.42

52-Week Range29.50 – 48.18

Volume4.09M

Market Cap21.39B

P/E (TTM)25.87

Forward P/E0.00

EPS1.19

Dividend Yield1.85%

50-Day Avg32.05

200-Day Avg36.11

About

Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. The company was founded in 2004 and is based in Weihai, China.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOMr. Cunming Zhang
Employees3.73K
HeadquartersNo. 7, Weigao West Road, Weihai, China, 264200, China
Websitehttps://www.wego-healthcare.com

Leadership

Mr. Cunming ZhangGM & Director · b. 1976
Mr. Jingang ZhangCFO & Accounting Supervisor · b. 1973
Ms. Xiaoyun ChenDeputy GM & Director · b. 1974
Mr. Changjun MouDeputy GM & Director · b. 1982
Ms. Tingting WangBoard Secretary · b. 1987
Mr. Ji WangDeputy General Manager · b. 1972

Financials

Income Statement

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	2.91B	3.43B	3.53B	3.60B	3.77B
Growth (%)	-	+17.71%	+3.09%	+2.03%	+4.57%
Cost of Revenue	1.56B	1.96B	1.99B	2.08B	2.25B
Gross Profit	1.35B	1.47B	1.54B	1.52B	1.52B
Gross Margin	46.45%	42.91%	43.74%	42.29%	40.23%
Operating Expense	1.00B	1.08B	0	967.36M	959.02M
Operating Income	350.64M	387.28M	1.54B	556.83M	557.04M
Operating Margin	12.05%	11.30%	43.74%	15.45%	14.78%
EBITDA	-	660.36M	689.93M	787.53M	824.90M
EBITDA Margin	-	19.27%	19.53%	21.85%	21.89%
Net Income	259.82M	314.96M	442.07M	449.37M	482.30M
Net Income Margin	8.93%	9.19%	12.52%	12.47%	12.80%
R&D	153.49M	182.84M	154.86M	164.70M	143.86M
R&D as % of Total Revenue	5.27%	5.34%	4.38%	4.57%	3.82%
Interest Expense	47.58M	54.99M	1.69M	601.10K	743.12K
Interest Expense % of Total Revenue	1.63%	1.60%	0.05%	0.02%	0.02%

Balance Sheet

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	5.94B	6.41B	6.68B	6.99B	8.61B
Total Liabilities	2.26B	1.74B	1.55B	1.39B	1.49B
Total Equity	3.68B	4.67B	5.14B	5.60B	7.12B
Cash	330.38M	588.96M	646.09M	818.09M	1.58B
Net Debt	348.80M	-	-	-	-

Cash Flow

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	504.89M	727.33M	288.14M	572.30M	793.71M
Capital Expenditure	401.25M	279.80M	232.81M	179.30M	159.85M
Free Cash Flow	103.64M	447.53M	288.14M	393.00M	633.86M
Dividends Paid	42.71M	18.84M	488.45K	-	65.83M
FCF to OCF	20.53%	61.53%	100.00%	68.67%	79.86%
Dividend Paid to FCF	41.21%	4.21%	0.17%	-	10.39%

Key Statistics & Ratios

Market Cap21.39B

Enterprise Value10.54B

Trailing P/E25.87

Forward P/E0.00

Price / Sales5.69

Price / Book1.82

EPS1.19

Book Value17.31

Revenue (TTM)3.76B

Gross Profit (TTM)1.45B

EBITDA798.77M

Profit Margin13.07%

Operating Margin12.20%

Return on Equity7.01%

Return on Assets4.07%

Shares Outstanding694.80M

Shares Float65.16M

Dividend Yield1.85%

Dividend Rate0.57

Payout Ratio43.56%

Dividends

20262×

0.21Sep 14, 20260.36Jun 1, 2026

20251×

0.16Oct 24, 2025